Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
At Shenzhen Hepalink Pharmaceutical Group Co., Ltd.’s Annual General Meeting, shareholders passed all proposed resolutions by a substantial majority. The resolutions included the company’s annual reports, profit distribution proposal, and strategic financial management decisions for 2023. The AGM, which featured a 60.29% shareholder attendance, confirmed the company’s plans for wealth management and bank credit facilities for the upcoming year.
For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.